Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical activity and immune correlates of glofitamab combined with tislelizumab in relapsed/refractory follicular lymphoma: A translational study

View Full Paper
Ask AI
Bookmark
Share

Authors

XLXianming LiuHebei University of Engineering

Discussion

Loading...

Member takes

Implication

Retrospective trial shows 100% overall response rate in relapsed follicular lymphoma, indicating success of immune-targeted therapy.

Key Points

  • Evaluate the clinical activity and safety of glofitamab with tislelizumab in relapsed follicular lymphoma patients.
  • Retrospective study of 12 patients with relapsed/refractory follicular lymphoma
  • Patients received obinutuzumab followed by step-up dosing of glofitamab and tislelizumab every 3 weeks
  • Endpoints included overall response rate, complete remission rate, minimal residual disease assessment, and safety monitoring.
  • Achieved 100% overall response rate with 83.3% complete remission
  • All complete responders showed minimal residual disease negativity by flow cytometry
  • Treatment was well-tolerated with mostly grade 1-2 cytokine release syndrome and no high-grade adverse events.

Cite This Study

Xianming Liu (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da0chttps://doi.org/10.1182/blood-2025-3595
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations
  2. 2Glofitamab combined with salvage therapy for relapsed or refractory aggressive B-cell lymphomas: Efficacy and safety in a real-world prospective observational study2025
  3. 3Real-world outcomes of glofitamab-based regimens in relapsed/refractory aggressive B-cell lymphoma2025
  4. 4A chemo-free tumor microenvironment (TME) reshaping regimen combining glofitamab induces a high CR rate in relapsed/refractory diffuse large B cell lymphoma (DLBCL)2025
  5. 5Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study.2024 · 3 citations